Investors Press Releases Sep 26 2023 Tiziana Life Sciences Initiates Multi-Center Phase 2a Clinical Trial of Intranasal Foralumab for Non-Active Secondary Progressive Multiple Sclerosis Read More Sep 08 2023 Tiziana Life Sciences to Participate in the H.C. Wainwright 25th Annual Global Investment Conference Read More Sep 06 2023 Study Validating MoA of Intranasal Foralumab in Alzheimer’s Disease Published in the Prestigious Journal PNAS, Following FDA IND Clearance Read More btn News View All Events & Presentations Jun 05 2023 at 12:30 PM EDT Jun 05 2023 at 12:30 PM EDT Tiziana Life Sciences: Foralumab Update in Non-Active Secondary Progressive Multiple Sclerosis (na SPMS) Read More Jan 09 2023 - Jan 11 2023 Jan 09 2023 - Jan 11 2023 Biotech Showcase Read More Dec 29 2022 Dec 29 2022 Annual General Meeting 2022 Read More btn Events View All Interim Reports Interim Results for the Six Months Ended 30 June 2022 641.6 KB bth Interim Reports View All Annual Reports 20 F - Annual Report for the year ended 31 December 2022 4.2 MB btn ARs View All Annual General Meeting Notice of Annual General Meeting December 2022 276.9 KB btn AGM View All Scientific Pipeline Progress Learn more × Stock Quote Change Volume Today's Open Previous Close Today's High Today's Low 52 Week High 52 Week Low Stock Chart
Sep 26 2023 Tiziana Life Sciences Initiates Multi-Center Phase 2a Clinical Trial of Intranasal Foralumab for Non-Active Secondary Progressive Multiple Sclerosis Read More
Sep 08 2023 Tiziana Life Sciences to Participate in the H.C. Wainwright 25th Annual Global Investment Conference Read More
Sep 06 2023 Study Validating MoA of Intranasal Foralumab in Alzheimer’s Disease Published in the Prestigious Journal PNAS, Following FDA IND Clearance Read More
Jun 05 2023 at 12:30 PM EDT Jun 05 2023 at 12:30 PM EDT Tiziana Life Sciences: Foralumab Update in Non-Active Secondary Progressive Multiple Sclerosis (na SPMS) Read More